Last 29 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.55 | — | — | — | — | — | — | — | — | — | — | — | 2.30 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | 42.21 | 12.10 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 8.09 | 6.48 | — | — | 11.17 | 4.19 | 2.73 | 2.25 | 3.33 | 4.67 | 3.03 | 3.13 | 2.55 |
| — | +54.6% | — | — | +234.9% | -10.3% | -9.8% | -28.2% | +30.6% | -7.7% | +0.9% | +16.3% | +4.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | -1550.2% | -393.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | -1495.0% | -376.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -277.6% | -865.2% | — | -591.1% | -66.5% | -33.7% | -26.0% | -36.5% | -60.1% | -43.8% | -34.0% | -24.9% | -18.4% |
| — | -2466.0% | — | -1518.4% | -10.7% | +23.0% | +23.4% | -46.9% | -227.4% | -146.3% | -91.4% | -89.3% | -30.5% | |
| ROA | -55.1% | -17.6% | -23.7% | -30.2% | -15.6% | -11.0% | -10.1% | -12.1% | -16.8% | -16.4% | -15.4% | -16.1% | -16.4% |
| — | -60.7% | -134.7% | -149.9% | +6.8% | +33.0% | +34.4% | +24.9% | -2.0% | +0.4% | +8.7% | -29.8% | -23.5% | |
| ROIC | -64.8% | -65.7% | -3553.2% | -65.5% | -17.3% | -10.5% | -9.4% | -11.5% | -16.7% | -18.0% | -28.1% | -25.6% | -19.9% |
| — | -524.9% | -37720.7% | -471.3% | -3.2% | +41.7% | +66.5% | +55.2% | +16.0% | +46.9% | +63.1% | +89.9% | +87.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 46.5% YoY to 8.24x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.17 | 2.79 | — | — | 4.17 | 2.25 | 1.67 | 1.32 | 3.09 | 1.79 | 1.25 | 0.92 | 0.04 |
| — | +24.0% | — | — | +35.0% | +25.7% | +33.7% | +42.8% | +8122.8% | +5255.7% | +19417.3% | +14609.8% | +505.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.10 | 8.24 | 4.97 | 4.67 | 9.10 | 15.40 | 19.13 | 22.75 | 10.11 | 10.45 | 13.89 | 13.63 | 11.70 |
| — | -46.5% | -74.0% | -79.5% | -10.0% | +47.4% | +37.7% | +67.0% | -13.6% | -17.8% | -34.7% | -40.2% | -33.4% | |
| Quick Ratio | 9.10 | 8.24 | 4.97 | 4.67 | 9.10 | 15.40 | 19.13 | 22.75 | 10.11 | 10.45 | 13.89 | 13.63 | 11.70 |
| — | -46.5% | -74.0% | -79.5% | -10.0% | +47.4% | +37.7% | +67.0% | -13.6% | -17.8% | -34.7% | -40.2% | -33.4% | |
| Interest Coverage | — | -12.31 | -13.18 | -21.95 | -13.51 | -10.65 | -10.89 | -12.01 | -16.19 | -18.26 | -20.04 | -469.76 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonMilestone Pharmaceuticals Inc.'s current P/E is -2.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Milestone Pharmaceuticals Inc.'s business trajectory between earnings reports.